Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes.

ABSTRACT:

Background

Using emicizumab in lieu of immune tolerance induction (ITI) for patients with hemophilia A (HA) and factor (F)VIII inhibitors has been well described. However, decisions regarding ITI initiation, regimen, and preservation of tolerance remain to be elucidated.

Objectives

To study the course of FVIII inhibitors in patients with HA and a history of FVIII inhibitors receiving emicizumab prophylaxis.

Methods

Patients with HA, with and without FVIII inhibitors, initiating emicizumab prophylaxis were prospectively followed up in our center. All patients with current or previous inhibitors were included in this analysis. Plasma samples for FVIII inhibitor assays were obtained every 3 to 6 months or following FVIII exposure. Patients documented annual bleeding rate

SUBMITTER: Levy-Mendelovich S 

PROVIDER: S-EPMC10394563 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature